The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Open accessAbstract
// Wenfeng Fang 1,2,* , Jianwei Zhang 3,* , Shaodong Hong 1,2,* , Jianhua Zhan 1,2,* , Nan Chen 4 , Tao Qin 1,2 , Yanna Tang 4 , Yaxiong Zhang 1,2 , Shiyang Kang 1,2 , Ting Zhou 1,2 , Xuan Wu 1,2 , Wenhua Liang 1,2 , Zhihuang Hu 1,2 , Yuxiang Ma 1,2 , Yuanyuan Zhao 1,2 , Ying Tian 1,2 , Yunpeng Yang 1,2 , Cong Xue 1,2 , Yue Yan 1,2 , Xue Hou 1,2 , Peiyu Huang 1,2 , Yan Huang 1,2 , Hongyun Zhao 1,2 and Li Zhang 1,2 1 State Key laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China 2 Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China 3 Department of Oncology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China 4 Department of Oncology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China * These authors contributed equally to this work Correspondence: Li Zhang, email: // Keywords : Nasopharyngeal carcinoma (NPC); latent membrane protein 1 (LMP1); PD-L1; Epstein–Barr virus (EBV) Received : July 20, 2014 Accepted : October 21, 2014 Published : October 21, 2014 Abstract PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was higher in EBV positive NPC cell lines compared with EBV negative cell lines. PD-L1 expression could be increased by exogenous and endogenous induction of LMP1 induced PD-L1. In agreement, expression of PD-L1 was suppressed by knocking down LMP1 in EBV positive cell lines. We further demonstrated that LMP1 up-regulated PD-L1 through STAT3, AP-1, and NF-κB pathways. Besides, IFN-γ was independent of but synergetic with LMP1 in up-regulating PD-L1 in NPC. Furthermore, we showed that PD-L1 was associated with worse disease-free survival in NPC patients. These results imply that blocking both the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may be a promising therapeutic approach for EBV positive NPC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Epstein–Barr virus: 40 years on
Young, L. S., & Rickinson, A. B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1452 · Cited by 2,227
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. M., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 843
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Badoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2606 · Cited by 633
Quantitative Analysis of Epstein-Barr Virus Load by Using a Real-Time PCR Assay
Kimura, H., Morita, M., Yabuta, Y., Kuzushima, K., Kato, K., Kojima, S., Matsuyama, T., & Morishima, T. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.1.132-136.1999 · Cited by 577
Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2599 · Cited by 569
Lee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446
Self-citationClinical impact of programmed cell death ligand 1 expression in colorectal cancer
Droeser, R. A., Hirt, C., Viehl, C. T., Frey, D. M., Nebiker, C., Huber, X., Zlobec, I., Eppenberger-Castori, S., Tzankov, A., Rosso, R., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.015 · Cited by 431
PD‐1 as a potential target in cancer therapy
McDermott, D. F., & Atkins, M. B. (2013) · Cancer Medicine · doi:10.1002/cam4.106 · Cited by 414
Lipson, E. J., Vincent, J. G., Loyo, M., Kagohara, L. T., Luber, B. S., Wang, H., Xu, H., Nayar, S. K., Wang, T. S., Sidransky, D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0034 · Cited by 378
Dawson, C. W., Port, R. J., & Young, L. S. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.004 · Cited by 355
Is nasopharyngeal cancer really a "Cantonese cancer"?
Wee, J. T. S., Ha, T., Loong, S. L. E., & Qian, C.-N. (2010) · 癌症:英文版 · doi:10.5732/cjc.009.10329 · Cited by 220
The battle against nasopharyngeal cancer
Lee, A. W. M., Ng, W. T., Chan, Y. H., Sze, H., Chan, C., & Lam, T. H. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.08.001 · Cited by 219
Gong, A.-Y., Zhou, R., Hu, G., Li, X., Splinter, P. L., O'Hara, S. P., LaRusso, N. F., Soukup, G. A., Dong, H., & Chen, X.-M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1325 · Cited by 217
Das, S., Suarez, G., Beswick, E. J., Sierra, J. C., Graham, D. Y., & Reyes, V. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.3000 · Cited by 184
Zeng, Z., Shi, F., Zhou, L., Zhang, M.-N., Chen, Y., Chang, X.-J., Lu, Y.-Y., Bai, W.-L., Qu, J.-H., Wang, C.-P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023621 · Cited by 169
Self-citationPD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dolan, D. E., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100308 · Cited by 145
Zheng, H., Li, L. L., Hu, D. S., Deng, X., & Cao, Y. (2007) · PubMed · Cited by 144
Wang, B. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i28.3322 · Cited by 144
Multiple roles of LMP1 in Epstein-Barr virus induced immune escape
Middeldorp, J. M., & Pegtel, D. M. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.10.004 · Cited by 143
Yoshizaki, T., Kondo, S., Wakisaka, N., Murono, S., Endo, K., Sugimoto, H., Nakanishi, S., Tsuji, A., & Ito, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.018 · Cited by 143
Zheng, Z., Bu, Z., Liu, X., Zhang, L., Li, Z., Wu, A., Wu, X., Cheng, X., Xing, X., Du, H., et al. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2014.02.08 · Cited by 125
Self-citationEpidemiology of Virus Infection and Human Cancer
Chen, C., Hsu, W.-L., Yang, H., Lee, M., Chen, H.-C., Chien, Y.-C., & You, S. (2013) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-38965-8_2 · Cited by 103
Morris, M. A., Dawson, W. O., & Young, L. S. (2009) · Future Oncology · doi:10.2217/fon.09.53 · Cited by 98
Li, J., Zeng, X., Mo, H., Rolén, U., Gao, Y.-F., Zhang, X., Chen, Q.-Y., Zhang, L., Zeng, M., Li, M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001122 · Cited by 91
Self-citationLi, T., Yang, W., Li, M., Byun, D., Tong, C., Nasser, S., Zhuang, M., Arango, D., Mariadason, J. M., & Augenlicht, L. H. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700331 · Cited by 90
Yang, G.-D., Huang, T.-J., Peng, L.-X., Yang, C.-F., Liu, R., Huang, H.-B., Chu, Q.-Q., Yang, H.-J., Huang, J.-L., Zhu, Z.-Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078355 · Cited by 90
Role of LMP1 in immune control of EBV infection
Pai, S., & Khanna, R. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0412 · Cited by 45
Lin, X., Gudgeon, N. H., Hui, E. P., Jia, H., Qun, X., Taylor, G. S., Barnardo, M., Lin, C. K., Rickinson, A. B., & Chan, A. T. �. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0427-8 · Cited by 41
Smith, P. A., Merritt, D., Barr, L., & Thorley‐Lawson, D. A. (2011) · Genes & Cancer · doi:10.1177/1947601912440878 · Cited by 30
Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance
Chen, X., Su-xu, Y., Chen, C., Mao, Y., Xu, G., & Wang, X. (2009) · 癌症:英文版 · doi:10.5732/cjc.009.10245 · Cited by 25
Cited by
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Chua, M. L. K., Wee, J. T. S., Hui, E. P., & Chan, A. T. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00055-0 · Cited by 1,236
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Metadata
- Authors
- Fang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., Tang, Y., Zhang, Y., Kang, S., Zhou, T., Wu, X., Liang, W., Hu, Z., Ma, Y., Zhao, Y., Tian, Y., Yang, Y., Xue, C., Yan, Y., Hou, X., Huang, P., Huang, Y., Zhao, H., & Zhang, L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-10-21
- Volume
- 5
- Issue
- 23
- Pages
- 12189-12202
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2104350866
- Cited by
- 398
- References
- 47
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.